Workflow
IRadimed (IRMD) Lags Q4 Earnings Estimates
IRMDiRadimed(IRMD) ZACKS·2025-02-13 15:46

Company Performance - iRadimed reported quarterly earnings of 0.44pershare,missingtheZacksConsensusEstimateof0.44 per share, missing the Zacks Consensus Estimate of 0.45 per share, but showing an increase from 0.39pershareayearago,resultinginanearningssurpriseof−2.220.39 per share a year ago, resulting in an earnings surprise of -2.22% [1] - The company posted revenues of 19.39 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.57% and increasing from 17.45millionyear−over−year[2]−Overthelastfourquarters,iRadimedhassurpassedconsensusEPSestimatesthreetimesandtoppedconsensusrevenueestimatesfourtimes[2]StockOutlook−iRadimedshareshavegainedabout1017.45 million year-over-year [2] - Over the last four quarters, iRadimed has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Outlook - iRadimed shares have gained about 10% since the beginning of the year, outperforming the S&P 500's gain of 2.9% [3] - The current consensus EPS estimate for the coming quarter is 0.42 on revenues of 19.46million,andforthecurrentfiscalyear,itis19.46 million, and for the current fiscal year, it is 1.72 on revenues of $80.81 million [7] - The estimate revisions trend for iRadimed is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Instruments industry, to which iRadimed belongs, is currently in the top 34% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]